XML 44 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8
Research And Collaboration Agreements (Cobimetinib Collaboration To Bristol-Meyers Squibb) (Details) (USD $)
12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2013
Glaxo SmithKline [Member]
Mar. 31, 2010
Genentech [Member]
Mar. 31, 2008
Genentech [Member]
Jan. 31, 2007
Genentech [Member]
Dec. 31, 2006
Genentech [Member]
Dec. 31, 2013
Genentech [Member]
Dec. 31, 2012
Genentech [Member]
Dec. 31, 2011
Genentech [Member]
Dec. 31, 2013
Genentech [Member]
Profit Sharing Tier One [Member]
Dec. 31, 2013
Genentech [Member]
Profit Sharing Tier Two [Member]
Oct. 31, 2002
Glaxo SmithKline [Member]
Dec. 31, 2013
Glaxo SmithKline [Member]
Dec. 31, 2012
Glaxo SmithKline [Member]
Dec. 31, 2011
Glaxo SmithKline [Member]
Oct. 31, 2011
Glaxo SmithKline [Member]
Jul. 31, 2011
Bristol-Myers Squibb [Member]
ROR Collaboration Agreement [Member]
Nov. 30, 2010
Bristol-Myers Squibb [Member]
ROR Collaboration Agreement [Member]
Dec. 31, 2013
Bristol-Myers Squibb [Member]
ROR Collaboration Agreement [Member]
Dec. 31, 2012
Bristol-Myers Squibb [Member]
ROR Collaboration Agreement [Member]
Dec. 31, 2011
Bristol-Myers Squibb [Member]
ROR Collaboration Agreement [Member]
Nov. 30, 2010
Bristol-Myers Squibb [Member]
TGR5 License Agreement [Member]
Jan. 31, 2010
Bristol-Myers Squibb [Member]
LXR Collaboration [Member]
Jan. 31, 2009
Bristol-Myers Squibb [Member]
LXR Collaboration [Member]
Dec. 31, 2007
Bristol-Myers Squibb [Member]
LXR Collaboration [Member]
Dec. 31, 2005
Bristol-Myers Squibb [Member]
LXR Collaboration [Member]
Dec. 31, 2013
Bristol-Myers Squibb [Member]
LXR Collaboration [Member]
product
Dec. 31, 2013
Bristol-Myers Squibb [Member]
Terminated Collaborations [Member] [Member]
Dec. 31, 2012
Bristol-Myers Squibb [Member]
Terminated Collaborations [Member] [Member]
Dec. 31, 2011
Bristol-Myers Squibb [Member]
Terminated Collaborations [Member] [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                                                
Upfront and milestone payments             $ 15,000,000.0 $ 25,000,000.0           $ 65,000,000.0                                    
Payment to use exercise of option related to co-development agreement           3,000,000.0                                                    
Milestone payment         7,000,000.0                                                      
Percent of profits                       50.00% 30.00%                                      
Profit threshold                       200,000,000 400,000,000                                      
Optional percent of total sales                 25.00%                                              
Maximum Potential Milestone Payments 2,400,000,000                                                              
Percentage of Maximum Potential Milestone Payments - Clinical Development 10.00%                                                              
Percentage of Maximum Potential Milestone Payments - Regulatory 41.00%                                                              
Percentage of Maximum Potential Milestone Payments - Commercial 49.00%                                                              
Research and development funding and loan                           85,000,000.0                                    
Common stock, shares issued 184,533,651 183,697,213                       3,000,000       5,537,906                            
Percent of royalty on net sale       3.00%                                                        
Royalty Expense                             400,000                                  
Upfront cash payment                                       5,000,000               17,500,000.0        
Number of years for initial research                                                       2 years        
Maximum amount eligible for development and regulatory milestones                                       255,000,000                 138,000,000      
Number of products                                                         2      
Maximum amount eligible for royalties on sales under collaborations agreement                                                         225,000,000.0      
Income from development milestone                                     2,500,000.0               5,000,000.0          
Maximum amount eligible for commercial milestones under collaborations agreement                                               150,000,000                
License, contract and collaboration reimbursement revenues 16,321,000 47,450,000 289,636,000           0 0 0       0 0 0       1,500,000 2,900,000 2,800,000             14,800,000 28,400,000 168,900,000
Additional research fund                                                   7,700,000            
Research and development fund                                                 $ 5,800,000     $ 10,000,000.0